{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T21:10:03Z","timestamp":1784581803615,"version":"3.55.0"},"reference-count":73,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2018,8,12]],"date-time":"2018-08-12T00:00:00Z","timestamp":1534032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"UHK","award":["Long-term development plan"],"award-info":[{"award-number":["Long-term development plan"]}]},{"name":"Republic of Serbia","award":["Ministry of Defence and Ministry of Education, Science and Technological Development"],"award-info":[{"award-number":["Ministry of Defence and Ministry of Education, Science and Technological Development"]}]},{"name":"UHHK","award":["MH CZ-DRO 00179906"],"award-info":[{"award-number":["MH CZ-DRO 00179906"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Amifostine is well known cytoprotector which is efficient when administered before a wide range of antineoplastic agents. The aim of our study was to investigate amifostine effects on doxorubicin-induced toxic changes in rats. Amifostine (75 mg\/kg ip) was given 30 min before each dose of doxorubicin (cumulatively 20 mg\/kg ip, for 28 days). The animals\u2019 whole-body, liver, and kidney weight, serum biochemical examination, as well as microscopic examination of bone marrow, peripheral blood, liver, and kidney, were done on day 56 of the study. Hepatic and renal alterations were carefully quantified by semiquantitative grading scales\u2014hepatic and renal damage score, respectively. In amifostine-pretreated rats, the number of peripheral blood leukocytes was significantly higher in comparison to doxorubicin-only treated group, preferentially protecting neutrophils. In the same group of rats, hepatic and renal alterations associated with polymorphonuclear cell infiltrates were significantly less severe than those observed in animals receiving only doxorubicin. Our results showed that amifostine successfully protected rats against multiple-dose doxorubicin-induced toxicity by complex, and still not fully elucidated mechanisms of action.<\/jats:p>","DOI":"10.3390\/ijms19082370","type":"journal-article","created":{"date-parts":[[2018,8,13]],"date-time":"2018-08-13T11:27:13Z","timestamp":1534159633000},"page":"2370","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["The Efficacy of Amifostine against Multiple-Dose Doxorubicin-Induced Toxicity in Rats"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5137-2638","authenticated-orcid":false,"given":"Vesna","family":"Ja\u0107evi\u0107","sequence":"first","affiliation":[{"name":"Department of Experimental Toxicology and Pharmacology, National Poison Control Centre, Military Medical Academy, 11 Crnotravska St, 11000 Belgrade, Serbia"},{"name":"Medical Faculty of the Military Medical Academy, University of Defense in Belgrade, 1 Pavla Juri\u0161i\u0107a-\u0160turma St, 11000 Belgrade, Serbia"},{"name":"Department of Chemistry, Faculty of Science, University of Hradec Kralove, Rokitansk\u00e9ho 62, 50003 Hradec Kr\u00e1lov\u00e9, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktorija","family":"Dragojevi\u0107-Simi\u0107","sequence":"additional","affiliation":[{"name":"Medical Faculty of the Military Medical Academy, University of Defense in Belgrade, 1 Pavla Juri\u0161i\u0107a-\u0160turma St, 11000 Belgrade, Serbia"},{"name":"Centre for Clinical Pharmacology, Military Medical Academy, 11 Crnotravska St, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u017deljka","family":"Tatomirovi\u0107","sequence":"additional","affiliation":[{"name":"Medical Faculty of the Military Medical Academy, University of Defense in Belgrade, 1 Pavla Juri\u0161i\u0107a-\u0160turma St, 11000 Belgrade, Serbia"},{"name":"Institute for Pathology, Military Medical Academy, 11 Crnotravska St, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0493-8525","authenticated-orcid":false,"given":"Silva","family":"Dobri\u0107","sequence":"additional","affiliation":[{"name":"Medical Faculty of the Military Medical Academy, University of Defense in Belgrade, 1 Pavla Juri\u0161i\u0107a-\u0160turma St, 11000 Belgrade, Serbia"},{"name":"Institute for Scientific Information, University of Defense in Belgrade, 1 Pavla Juri\u0161i\u0107a-\u0160turma St, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dubravko","family":"Bokonji\u0107","sequence":"additional","affiliation":[{"name":"Medical Faculty of the Military Medical Academy, University of Defense in Belgrade, 1 Pavla Juri\u0161i\u0107a-\u0160turma St, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Kova\u010devi\u0107","sequence":"additional","affiliation":[{"name":"Medical Faculty of the Military Medical Academy, University of Defense in Belgrade, 1 Pavla Juri\u0161i\u0107a-\u0160turma St, 11000 Belgrade, Serbia"},{"name":"Centre for Clinical Pharmacology, Military Medical Academy, 11 Crnotravska St, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenie","family":"Nepovimova","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Faculty of Science, University of Hradec Kralove, Rokitansk\u00e9ho 62, 50003 Hradec Kr\u00e1lov\u00e9, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Vali\u0161","sequence":"additional","affiliation":[{"name":"Department of Neurology, Charles University in Prague, Faculty of Medicine in Hradec Kralove and University Hospital, Simkova 870, 50003 Hradec Kr\u00e1lov\u00e9, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9664-1109","authenticated-orcid":false,"given":"Kamil","family":"Ku\u010da","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Faculty of Science, University of Hradec Kralove, Rokitansk\u00e9ho 62, 50003 Hradec Kr\u00e1lov\u00e9, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2018,8,12]]},"reference":[{"key":"ref_1","first-page":"464","article-title":"Primary Chemotherapy in Operable Breast Cancer","volume":"23","author":"Bonadonna","year":"1998","journal-title":"Semin. Oncol."},{"key":"ref_2","unstructured":"Dollery, C. (1999). Cyclophosphamide. Therapeutic Drugs, Churchill Livingstone. [2nd ed.]. ISBN-10: 0443051488, ISBN-13: 978-0443051487."},{"key":"ref_3","first-page":"1","article-title":"Anthracyclines in the Treatment of Cancer. An Overview","volume":"54","author":"Hortobagyi","year":"1997","journal-title":"Drugs"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0006-2952(98)00307-4","article-title":"A Critical Evaluation of the Mechanisms of Action Proposed for the Antitumor Effects of the Anthracycline Antibiotics Adriamycin and Daunorubicin","volume":"57","author":"Gewitz","year":"1999","journal-title":"Biochem. Pharmacol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1124\/pr.56.2.6","article-title":"Anthracyclines: Molecular Advances and Pharmacologic Development in Antitumor Activity and Cardiotoxicity","volume":"56","author":"Minoti","year":"2004","journal-title":"Pharmacol. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/0277-5379(91)90409-7","article-title":"New Anthracycline Derivates: What for?","volume":"27","author":"Mross","year":"1991","journal-title":"Eur. J. Cancer Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ejphar.2010.05.002","article-title":"Inhibition of Gene Expression of Heart Fatty Acid Binding Protein and Organic Cation\/Carnitine Transporter in Doxorubicin Cardiomyopathic Rat Model","volume":"640","author":"Hafez","year":"2010","journal-title":"Eur. J. Pharmacol."},{"key":"ref_8","unstructured":"Martindale (2011). The Complete Drug Reference [CD-ROM], Pharmaceutical Press. [36th ed.]. ISBN-13: 978-0853698425, ISBN-10: 0853698422."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1006\/phrs.2000.0769","article-title":"The Preventive Role of Deferoxamine against Acute Doxorubicin Induced Cardiac, Renal and Hepatic Toxicity in Rats","volume":"43","author":"Saad","year":"2000","journal-title":"Pharmacol. Res."},{"key":"ref_10","first-page":"1142","article-title":"Reduced Progression of Adriamycin Nephropathy in Spontaneously Hypertensive Rats Treated by Losartan","volume":"24","year":"2009","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.3892\/etm.2014.1535","article-title":"Prevention of Adriamycin-Induced Hepatic and Renal Toxicity in Male BALB\/c Mice by a Nutrient Mixture","volume":"7","author":"Roomi","year":"2014","journal-title":"Exp. Ther. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"38","DOI":"10.2298\/VSP110905041D","article-title":"Efficacy of amifostine in protection against doxorubicin-induced acute cardiotoxic effects in rats","volume":"70","year":"2013","journal-title":"Vojnosanit. Pregl."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s002800050048","article-title":"Comparison of the Protective Effects of Amifostine and Dexrazoxane against the Toxicity of Doxorubicin in Spontaneously Hypertensive Rats","volume":"45","author":"Herman","year":"2000","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_14","first-page":"23","article-title":"Comparative Toxicity of Mitoxantrone and Doxorubicin on Hematopoietic Stem Cells","volume":"13","author":"Okunewick","year":"1985","journal-title":"Exp. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.lfs.2018.03.023","article-title":"Toxicity of Doxorubicin (Dox) to Different Experimental Organ Systems","volume":"200","author":"Pugazhendhi","year":"2018","journal-title":"Life Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.yjmcc.2012.03.006","article-title":"Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies","volume":"52","author":"Octavia","year":"2012","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_17","first-page":"466","article-title":"Histopathological effects of cisplatin, doxorubicin and 5-flurouracil (5-FU) on the liver of male albino rats","volume":"5","author":"Ismail","year":"2009","journal-title":"Int. J. Biol. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"390238","DOI":"10.1155\/2011\/390238","article-title":"Doxorubicin induced nephrotoxicity: Protective effect of nicotinamide","volume":"2011","author":"Ayla","year":"2011","journal-title":"Int. J. Cell Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"282","DOI":"10.2174\/156720212803530636","article-title":"Doxorubicin-induced in vivo nephrotoxicity involves oxidative stress-mediated multiple pro- and anti-apoptotic signaling pathways","volume":"9","author":"Lahoti","year":"2012","journal-title":"Curr. Neurovasc. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/BF00262774","article-title":"Epirubicin and Doxorubicin Comparative Metabolism and Pharmacokinetics","volume":"21","author":"Camaggi","year":"1988","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0026-895X(25)09888-8","article-title":"Oxigen Dependent Hepatotoxicity Due to Doxorubicin: Role of Reducing Equivalent Supply in Perfused Rat Liver","volume":"34","author":"Ganey","year":"1988","journal-title":"Mol. Pharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/BF00252979","article-title":"Hepatic Extraction, Metabolism and Biliary Excretion of Doxorubicin in the Isolated Perfused Rat Liver","volume":"19","author":"Ballet","year":"1987","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_23","first-page":"1036","article-title":"Loss of Fluorescence by Anthracycline Antibiotics: Effects of Xanthine Oxidase and Identification of the Nonfluorescent Metabolites","volume":"47","author":"Dodion","year":"1987","journal-title":"Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1073\/pnas.1321783111","article-title":"Doxorubicin-Induced Carbonylation of Cardiac Myosin Binding Protein C Promote Cardiotoxicity","volume":"111","author":"Aryal","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"301982","DOI":"10.1155\/2013\/301982","article-title":"Oxidative Stress and Nucleic Acid Oxidation in Patients with Chronic Kidney Disease","volume":"2013","author":"Sung","year":"2013","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Karanovic, D., Grujic-Milanovic, J., Miloradovic, Z., Ivanov, M., Jovovic, D.J., Vajic, U.J., Zivotic, M., Markovic-Lipkovski, J., and Mihailovic-Stanojevic, N. (2016). Effects of Single and Combined Losartan and Tempol Treatments on Oxidative Stress, Kidney Structure and Function in Spontaneously Hypertensive Rats with Early Course of Proteinuric Nephropathy. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0161706"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2298\/SARH0204073J","article-title":"Slowing Progression of Chronic Renal Insufficiency with Captopril in Rats with Spontaneous Arterial Hypertension and Adriamycin Nephropathy","volume":"130","year":"2002","journal-title":"Srp. Arh. Celok. Lek."},{"key":"ref_28","first-page":"428","article-title":"Doxorubicin Toxicity Can be Ameliorated during Antioxidant L-Carnitine Supplementation","volume":"2","author":"Alshabanah","year":"2014","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_29","first-page":"819","article-title":"Anti-Inflammatory Activity of Fullerenol C60(OH)24 Nano-Particles in a Model of Acute Inflammation in Rats","volume":"6","author":"Jacevic","year":"2011","journal-title":"Dig. J. Nanomater. Biostruct."},{"key":"ref_30","first-page":"108","article-title":"Dosing considerations with amifostine: A Review of the Literature and Clinical Experience","volume":"26","author":"Dorr","year":"1999","journal-title":"Semin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1089\/ars.2012.4795","article-title":"Oxidative Stress, Redox Signaling, and Metal Chelation in Anthracycline Cardiotoxicity and Pharmacological Cardioprotection","volume":"18","author":"Sterba","year":"2013","journal-title":"Antioxid. Redox Signal."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.yexmp.2017.03.005","article-title":"Fullerenol Nanoparticles Prevents Doxorubicin-Induced Acute Hepatotoxicity in Rats","volume":"102","author":"Jacevic","year":"2017","journal-title":"Exp. Mol. Pathol."},{"key":"ref_33","first-page":"169","article-title":"Amifostine Protection against Doxorubicin Cardiotoxicity in Rats","volume":"15","author":"Dobric","year":"2004","journal-title":"Anti Cancer Drugs"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.2165\/00003495-199550060-00008","article-title":"Amifostine: A review of Its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Potential as a Radioprotector and Cytotoxic Chemoprotector","volume":"50","author":"Spencer","year":"1995","journal-title":"Drugs"},{"key":"ref_35","first-page":"3","article-title":"The Preclinical Basis for Broad-Spectrum Selective Cytoprotection of Normal Tissue from Cytotoxic Therapies by Amifostine","volume":"26","author":"Capizzi","year":"1999","journal-title":"Semin. Oncol."},{"key":"ref_36","first-page":"738","article-title":"Amifostine: The First Selective-Target and Broad-Spectrum Radioprotector","volume":"12","author":"Kouvaris","year":"2007","journal-title":"Oncology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/0360-3016(88)90387-2","article-title":"Final Report On Phase I Trial of WR-2721 before Protracted Fractionated Radiation Therapy","volume":"14","author":"Kligerman","year":"1988","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_38","first-page":"3","article-title":"Differential Protection against Cytotoxic Chemotherapeutic Effects on Bone Marrow CFUs by WR-2721","volume":"4","author":"Wasserman","year":"1981","journal-title":"Cancer Clin. Trial"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1182\/blood.V83.11.3132.3132","article-title":"Amifostine (WR-2721) Shortens the Engraftment Period of 4-hydroperoxy-Cyclophosphamide-Purged Bone Marrow in Breast Cancer Patients Receiving High-Dose Chemotherapy with Autologous Bone Marrow Support","volume":"83","author":"Shpall","year":"1994","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1600-0773.1994.tb00330.x","article-title":"Cardiotoxicity of Doxorubicin: Effects of Drugs Inhibiting the Release of Vasoactive Substances","volume":"75","author":"Rossi","year":"1994","journal-title":"Pharmacol. Toxicol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/BF00686629","article-title":"Comparison of the Protective Effects of Desferrioxamine and ICRF-187 against Doxorubicin-Induced Toxicity in Spontaneously Hypertensive Rats","volume":"35","author":"Herman","year":"1994","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_42","first-page":"6918","article-title":"Effects of Pretreatment with ICRF-187 on the Total Cumulative Dose of Doxorubicin Tolerated by Beagle Dogs","volume":"48","author":"Herman","year":"1988","journal-title":"Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/0041-008X(88)90226-8","article-title":"Protective Effects of ICRF-187 on Doxorubicin-Induced Cardiac and Renal Toxicity in Spontaneously Hypertensive Rats","volume":"92","author":"Herman","year":"1988","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_44","first-page":"194","article-title":"Comparative Study of Doxorubicin, Mitoxantrone, and Epirubicin in Combination with ICRF-187 (ADR-529) in Chronic Cardiotoxicity Animal Model","volume":"52","author":"Alderton","year":"1992","journal-title":"Cancer Res."},{"key":"ref_45","first-page":"738","article-title":"Preclinical Evaluation of WR-151327: An Orally Active Chemotherapy Protector","volume":"54","author":"Green","year":"1994","journal-title":"Cancer Res."},{"key":"ref_46","first-page":"1137","article-title":"Inhibition of DNA and RNA Metabolism by Daunomycin and Adriamycin in L1210 Mouse Leukemia","volume":"32","author":"Meriweather","year":"1972","journal-title":"Cancer Res."},{"key":"ref_47","first-page":"28","article-title":"Migration of the Macrophages to the Thymus after Cyclophosphamide","volume":"53","author":"Castaldi","year":"1972","journal-title":"Br. J. Exp. Pathol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1038\/sj.leu.2401151","article-title":"Amifostine Stimulates Formation of Multipotent and Erythroid Bone Marrow Progenitors","volume":"12","author":"List","year":"1998","journal-title":"Leukemia"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1182\/blood.V86.7.2849.2849","article-title":"Amifostine Improves the Antileukemic Therapeutic Index of Mafosfamide: Implications for Bone Marrow Purging","volume":"86","author":"Douau","year":"1995","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4060","DOI":"10.1182\/blood.V94.12.4060","article-title":"Amifostine Inhibits Hematopoietic Progenitor Cell Apoptosis by Activating NF-\u03baB\/Rel Transcription Factors","volume":"94","author":"Romano","year":"1999","journal-title":"Blood"},{"key":"ref_51","first-page":"291","article-title":"Amifostine is a Potent Stimulant of Hematopoietic Progenitors","volume":"36","author":"List","year":"1995","journal-title":"Proc. Am. Assoc. Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1182\/blood.V72.4.1230.1230","article-title":"Granulocyte Macrophage Colony-Stimulating Activity Production by Cultured Human Thymic Nonlymphoid Cells Is Regulated by Endogenous Interleukin 1","volume":"72","author":"Ridgway","year":"1988","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2307\/3577370","article-title":"Radioprotection of Mice with Interleukin 1: Relationship to the Number of Spleen Colony-Forming Units","volume":"119","author":"Schwartz","year":"1989","journal-title":"Radiat. Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.4049\/jimmunol.139.6.1861","article-title":"The In Vivo Effects of Interleukin 1. I. Bone Marrow Cells Are Induced to Cycle after Administration of Interleukin 1","volume":"139","author":"Neta","year":"1987","journal-title":"J. Immunol."},{"key":"ref_55","first-page":"6218","article-title":"Mechanism of Diethyldithiocarbamate Modulation of Murine Bone Marrow Toxicity","volume":"50","author":"Schmalbach","year":"1990","journal-title":"Cancer Res."},{"key":"ref_56","first-page":"3955","article-title":"Prevention of Doxorubicin-Induced Hematotoxicity in Mice by Interleukin 1","volume":"49","author":"Eppstein","year":"1989","journal-title":"Cancer Res."},{"key":"ref_57","first-page":"16","article-title":"Adriamycin-Induced Nephrotic Syndrome in Rats. Sequence of Pathologic Events","volume":"46","author":"Bertani","year":"1982","journal-title":"Lab. Investig."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/ki.1986.28","article-title":"Adriamycin-Induced Nephropathy as a Model of Chronic Progressive Glomerular Disease","volume":"29","author":"Okuda","year":"1986","journal-title":"Kidney Int."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"8601","DOI":"10.3390\/molecules16108601","article-title":"The Protective Effects of Silymarin against Doxorubicin-Induced Cardiotoxicity and Hepatotoxicity in Rats","volume":"16","author":"Mikov","year":"2011","journal-title":"Molecules"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"18314","DOI":"10.1038\/srep18314","article-title":"Protective Effects of Madecassoside against Doxorubicin Induced Nephrotoxicity in Vivo and in Vitro","volume":"5","author":"Su","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1634\/theoncologist.6-2-162","article-title":"Hepatotoxicity of Chemotherapy","volume":"6","author":"King","year":"2001","journal-title":"Oncologist"},{"key":"ref_62","first-page":"364","article-title":"Current Concepts of Neurohormonal Activation in Heart Failure: Mediators and Mechanisms","volume":"19","author":"Lee","year":"2008","journal-title":"AACN Adv. Crit. Care"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/MNH.0b013e3282f357da","article-title":"Renal Hemodynamics in Heart Failure: Implications for Treatment","volume":"17","author":"Rea","year":"2008","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1006\/jmcc.1998.0842","article-title":"Secondary Endothelial Dysfunction: Hypertension and Heart Failure","volume":"31","author":"Boulanger","year":"1999","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1755-5922.2009.00094.x","article-title":"Neuroendocrine Effects on the Heart and Targets for Therapeutic Manipulation in Heart Failure","volume":"27","author":"Chaggar","year":"2009","journal-title":"Cardiovasc. Ther."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"El-Sayed, M., Mansour, A.M., and El-Sawy, W.S. (2017). Protective Effect of Proanthocyanidins against Doxorubicin-Induced Nephrotoxicity in Rats. J. Biochem. Mol. Toxicol., 31.","DOI":"10.1002\/jbt.21965"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.yexmp.2018.04.005","article-title":"Hepatoprotective Effect of Fullerenol\/Doxorubicin Nanocomposite in Acute Treatment of Healthy Rats","volume":"104","author":"Petrovic","year":"2018","journal-title":"Exp. Mol. Pathol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s002800050026","article-title":"In Vitro Antioxidant Properties of Amifostine (WR-2721, Ethyol)","volume":"45","author":"Marzatico","year":"2000","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/bcpt.12086","article-title":"Activity of Dexrazoxane and Amifostine against Late Cardiotoxicity Induced by the Combination of Doxorubicin and Cyclophosphamide In Vivo","volume":"113","author":"Bjelogrlic","year":"2013","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_70","first-page":"1","article-title":"Antioxidant and Genoprotective Effects of Amifostine against Irinotecan Toxicity in Human Hepatoma Cells","volume":"3","author":"Shokrzadeh","year":"2018","journal-title":"Int. J. Cancer Res. Ther."},{"key":"ref_71","first-page":"123","article-title":"Gastroprotective Effects of Amifostine in Rats Treated by T-2 Toxin","volume":"37","author":"Jacevic","year":"2018","journal-title":"Toxicol. Rev."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0022-3565(25)38810-5","article-title":"Doxorubicin Cardiotoxicity: Contractile Changes after Long Term Treatment in the Rat","volume":"236","author":"Jensen","year":"1986","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jab.2016.05.004","article-title":"Effects of Fullerenol Nanoparticles and Amifostine on Radiation-Induced Tissue Damages: Histopathological Analysis","volume":"14","author":"Jacevic","year":"2016","journal-title":"J. Appl. Biomed."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/19\/8\/2370\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:18:15Z","timestamp":1760195895000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/19\/8\/2370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,12]]},"references-count":73,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,8]]}},"alternative-id":["ijms19082370"],"URL":"https:\/\/doi.org\/10.3390\/ijms19082370","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,12]]}}}